TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Prospective Study to Observe the Mechanism of Action of the MediTate iTind in Subjects With Symptomatic BPH With MRI

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject signed informed consent form (ICF)~* Age 40 and above- Male with symptomatic BPH.~* IPSS symptom severity score ≥ 13~* Peak urinary flow of \< 12 ml/sec~* Prostate volume between 25 ml to 80 ml (assessed by pre-operative ultrasound - TRUS)~* Blood CBC and biochemistry up to two weeks before screening, demonstrating: Normal values of the PT, PTT and INR tests (Anticoagulants washout may be done two weeks prior of device implantation)~* Subject able to comply with the study protocol~* Normal urinalysis and negative urine culture~* Subjects that are able to undergo MRI.~Exclusion Criteria:~* A post void residual (PVR) volume \> 250 ml measured by ultrasound or acute urinary retention~* Confirmed or suspected bladder cancer;~* Recent (within 3 months) cystolithiasis or hematuria;~* Urethral strictures, bladder neck contracture, urinary bladder stones or other potentially confounding bladder pathology;~* An active urinary tract infection.~* Enrolled in another treatment trial for any disease within the past 30 days.~* Previous colo- rectal surgery (other than hemorrhoidectomy) or history of rectal disease if the therapy may potentially cause injury to sites of previous rectal surgery, e.g., if a transrectal probe is used;~* Previous pelvic irradiation, cryosurgery or radical pelvic surgery;~* Previous prostate surgery, balloon dilatation, stent implantation, laser prostatectomy, hyperthermia, or any other invasive treatment to the prostate~* Median lobe obstruction of the prostate (larger than 1cm).~* Cancer that is not considered cured, except basal cell or squamous cell carcinoma of the skin (cured defined as no evidence of cancer within the past 5 years)~* Patient with renal dysfunction~* Any serious medical condition likely to impede successful completion of the study

- Gender: MALE
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- iTind arm (Type: EXPERIMENTAL): ITind device implant

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Precise Recognition With Enhanced Vision of Endocrine Neck Targets

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Man or woman over 18 years old.~* Patient with benign or malignant pathology of the thyroid or parathyroid gland~* Patient with no contraindication to anesthesia and surgery~* Patient able to receive and understand information related to the study~* Patient affiliated to the French social security system.~Exclusion Criteria:~* Patient who needs an emergency surgery~* Pregnant or lactating patient.~* Patient under guardianship or trusteeship.~* Patient under the protection of justice.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Thyroids (Type: None): The aim is to identify and preserve the parathyroid glands during the total or partial removal of the thyroid. Repeating of the procedure for each lobe
- Parathyroids (Type: None): The aim is to selectively remove the pathological parathyroid gland(s). Repeating of the procedure for each removed gland

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Immunosenescence and Hepatitis B Virus (HBV) Vaccine Efficacy in Chronic Renal Disease Patient

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with an indication of HBV vaccination~* Patient with renal disease, with a creatinine clearance between 15 and 60ml/min~* Patient who have never been vaccinated against HBV~* Patient with negative serology for HBV~* Patient able to understand the reason of the study~* Patient not opposed to the conservation of biological samples for scientific research~Exclusion Criteria:~* Patient infected with Hepatitis B or with history of vaccination against HBV~* Patient suffering from psychotic illness~* Patient with any history of immunosuppressive therapy~* Patient with infectious and/or cancer diseases in evolution

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Chronic Renal Failure (Type: EXPERIMENTAL): Patients with renal failure, with creatinine clearance between 60 and 15 ml/min. A blood sample is achieved at 0, 1, 3 and 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed amyloidosis~  * No secondary familial or localized amyloidosis~* Presence of monoclonal protein by immunoelectrophoresis or immunofixation of serum or urine~* No primary amyloidosis manifested only by carpal tunnel syndrome or purpura~* Amyloid deposits in a plasmacytoma or in bone marrow vessels in an asymptomatic individual not considered an amyloid syndrome~  * Amyloid syndromes include any of the following:~    * Hepatomegaly~   * Cardiomyopathy~   * Nephrotic range proteinuria~   * Peripheral or autonomic neuropathy~* No multiple myeloma defined by 1 of the following:~  * Presence of lytic bone disease~ * More than 30% bone marrow plasma cells~PATIENT CHARACTERISTICS:~Age~* 18 to 70~Performance status~* ECOG 0-1~Life expectancy~* Not specified~Hematopoietic~* Platelet count at least 100,000/mm\^3~Hepatic~* See Disease Characteristics~* Total or direct bilirubin no greater than 2.0 mg/dL~* Alkaline phosphatase no greater than 4 times upper limit of normal~Renal~* See Disease Characteristics~* Creatinine less than 3.0 mg/dL~Cardiovascular~* See Disease Characteristics~* Ejection fraction at least 45% by echocardiogram~* No New York Heart Association class III or IV heart disease~* Systolic blood pressure ≥ 90 mmHg~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No active infection~* No other malignancy within the past 5 years except surgically treated carcinoma in situ of the cervix, nonmelanoma skin cancer, or indolent prostate cancer~PRIOR CONCURRENT THERAPY:~Biologic therapy~* At least 4 weeks since prior interferon~Chemotherapy~* At least 4 weeks since prior melphalan~* Lifetime total melphalan dose less than 150 mg/m\^2 (based on ideal body weight)~Endocrine therapy~* At least 4 weeks since prior dexamethasone~Radiotherapy~* No prior radiotherapy for amyloidosis~Surgery~* Not specified~Other~* No antihypertensive medications for at least 24 hours prior to, during, and for 1 hour after amifostine administration~* No other prior treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Amifostine, Melphalan, and Stem Cell Reconstitution (Type: EXPERIMENTAL): Amifostine, Melphalan, and Stem Cell Reconstitution. Doses of Melphalan tested included 100 mg/m2 and 120 mg/m2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Nitazoxanide Tablets in the Treatment of Mild to Moderate Active Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years.~* Diagnosis of Crohn's disease with colonic or perianal involvement confirmed by endoscopic, histologic and/or radiologic data.~* CDAI score ≥200 and ≤400.~Exclusion Criteria:~* Subjects known to have stool positive for Clostridium difficile toxin A or B, bacterial enteric pathogens, rotavirus, Cryptosporidium species (spp.), and/or ova/parasites.~* Evidence of bowel obstruction.~* Females that are pregnant, breast-feeding or not using birth control and are sexually active.~* Serious systemic disorders incompatible with the study.~* History of hypersensitivity to nitazoxanide or any inactive ingredient in the formulation.~* Uncontrolled gastro-intestinal bleeding.~* Evidence of intestinal abscess, non-perianal fistula or stricture.~* Patients who have received antibiotics in the past 7 days.~* Patients receiving \>20 mg of prednisone, or its equivalent.~* Patients receiving Anucort-HC or rectal steroids.~* Patients receiving immunosuppressive therapy that has not been stabilized.~* Patients who have received TNF-alpha inhibitor treatments such as infliximab or other biological agents within three months prior to start of treatment.~* Patients with Crohn's disease confined to the esophagus, stomach and small bowel.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): One nitazoxanide 500 mg tablet twice daily for 28 days
- 2 (Type: PLACEBO_COMPARATOR): One placebo tablet twice daily for 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cross Linking for Treatment of Corneal Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of infectious keratitis~Exclusion Criteria:~* corneal ulcer that has perforated~* corneal ulcer that has produced a descemetocele~* women who are pregnant or breastfeeding~* patients who are immunocompromised or unwilling or unable to comply with a medication regimen

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 30 minute light duration (Type: ACTIVE_COMPARATOR): 30 minute treatment with UVX light
- 45 minute light duration (Type: ACTIVE_COMPARATOR): 45 minute treatment with UVX light

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness and Safety Study of Pentosan Polysulfate Sodium for the Treatment of Interstitial Cystitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Must have a total score of 8 or greater on the O'Leary-Sant Interstitial Cystitis Symptom Index (ICSI) and a score of \> 0 on each of the 4 questions on the ICSI~* must have experienced bladder pain, urinary urgency and urinary frequency, each not related to a urinary tract infection, for at least 6 months prior to entry into the study~* must have averaged \>= 10 voids per day (\>=30 voids over 3 consecutive days) and averaged \>= 1 void at night~* urine culture showing no evidence of urinary tract infection~* urine cytology showing no evidence of neoplastic cells~Exclusion Criteria:~* Scheduled for or use of intravesical therapy (eg, bladder distention, dimethyl sulfoxide) during or within 4 weeks prior to the study~* patients who have had cytoscopic evaluation within 4 weeks prior to the study~* patients who are currently (within last month) receiving other medications that may affect symptoms of interstitial cystitis (ie, antidepressants, antihistamines, antispasmodics, anticholinergics)~* patients who are chronic users of Schedule II narcotics or who are using any scheduled narcotics at the time of study entry~* patients taking coumadin, anticoagulants, heparin, or thrombolytic agents such as tissue plasminogen activator and streptokinase

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pentosan polysulfate sodium 100 mg once a day (Type: EXPERIMENTAL): One 100 mg pentosan polysulfate sodium capsule in the morning and 1 matching placebo capsule in the afternoon and evening for 24 weeks
- Pentosan polysulfate sodium 100 mg three times a day (Type: EXPERIMENTAL): One 100 mg pentosan polysulfate sodium capsule 3 times a day (morning afternoon and evening) for 24 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo One placebo capsule 3 times a day (morning afternoon and evening) for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Remote Monitoring With Health-Coaching for Lifestyle Changes in Patients With Lung Cancer Related Fatigue

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with advanced lung non-small cell carcinoma (NSCLC) being treated with any line of non-curative intent, systemic treatment.~* Eastern Cooperative Oncology Group (ECOG) Performance Status from 0 (asymptomatic) to 2.~* The ability to read and respond to questions in English or Spanish~* Receiving primary cancer care at Mayo Clinic, Rochester or Mayo Clinic Health System (MCHS).~* Age \> 18 years.~* Life expectancy at least 6 months.~* Moderate or higher fatigue (\>= 4) on a scale of 0-10 based on fatigue rating to question: Rate your average fatigue over the last week, where 0 is no fatigue and 10 is extreme fatigue.~Exclusion Criteria:~* They have cognitive or psychiatric conditions as determined by the treating oncologist to prohibit study consent or participation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Supportive care (remote monitoring with health coaching) (Type: EXPERIMENTAL): Patients undergo routine exercise using a remote monitoring system (Garmin Vívofit activity monitor, Nonin 3150 WristOx2 pulse oximeter, and an Android tablet) over 30 minutes at least 6 days per week and complete daily questionnaires over 20 minutes for 12 weeks. Patients also receive health coaching telephone calls over 5-20 minutes once a week for 12 weeks. At the end of the 12 weeks, patients complete an audio taped telephone interview.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Chimerix CMX001 Registry

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Have previously completed study CMX001-301 through the Week 24 visit, or participated in another qualifying clinical study with CMX001.~* Willing and able to understand and provide written informed consent to participate in this observational study~* Willing and able to participate in all required study activities for the entire duration of the observational study (i.e., agreeable to being contacted at periodic intervals over the course of approximately 10 years following the completion of study CMX001-301 or other qualifying clinical study.~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- CMX001 (Type: None): Subjects who have previously participated in CMX001-301 or other CMX001 study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase I Study of TS-1 With Concurrent Radiotherapy to Treat Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* histologically or cytologically proven, newly diagnosed pancreatic adenocarcinoma or adenosquamous carcinoma~* no previous radiotherapy, chemotherapy, targeted therapy, curative surgery, or immunotherapy used for pancreatic cancer~* presence of at least one measurable lesion, which must meet the criteria of being ≥ 20 mm in at least one dimension by conventional CT/MRI or ≥ 10 mm by spiral CT scan~* age between 20 and 79 years at registration~* ECOG PS of 0 or 1~* adequate major organ functions~* ability to take the oral study medication (TS-1)~* no clinically significant abnormal ECG findings within 28 days (4 weeks) prior to registration~* voluntarily signed the written informed consent form~Exclusion Criteria:~* pulmonary fibrosis or interstitial pneumonitis diagnosed within 28 days prior to registration~* presence of diarrhea ≥ CTCAE v.4.03 grade 2~* concomitant active infection or significant co-morbid medical conditions~* moderate or severe ascites or pleural effusion that requires drainage~* central nervous system metastasis~* prior or concurrent malignancies within the last 3 years~* concomitant treatment with flucytosine, phenytoin or warfarin~* pregnant women or nursing mothers, or positive pregnancy test~* severe mental disorder~* judged ineligible by physician for participation in the study due to safety concern

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- S-1-CCRT (Type: EXPERIMENTAL): There are five dose levels and one arm only. Level 1: S-1, 25 mg/m2, bid, Day 1-14; RT 25 Gy/10 fx, Day 1-5, 8-12 Level 2: S-1, 25 mg/m2, bid, Day 1-14; RT 30 Gy/10 fx, Day 1-5, 8-12 Level 3: S-1, 30 mg/m2, bid, Day 1-14; RT 30 Gy/10 fx, Day 1-5, 8-12 Level 4: S-1, 30 mg/m2, bid, Day 1-16; RT 36 Gy/12 fx, Day 1-5, 8-12, 15-16 Level 5: S-1, 35 mg/m2, bid, Day 1-16; RT 36 Gy/12 fx, Day 1-5, 8-12, 15-16 All dose levels are followed by Gemcitabine/S-1 (G 1000 mg/m2, iv, D1 and 15 plus S-1 60/80/100 mg/day based on BSA, po, D1-7, D15-21, q4w) after the CCRT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Quantra® System With the QStat® Cartridge in Trauma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is \> 18 years; Children under the age of 18 are protected by adults under guardianship or by court order.~* Subject is a trauma patient experiencing traumatic injuries requiring a full trauma team response according to site's level 1of trauma team activation criteria.~* Subject, or subject's legally authorized representative (LAR), is willing to provide informed consent, either prospectively or by deferred consent.~Exclusion Criteria~* Subject is pregnant.~* Subject is currently enrolled in a distinct study that might confound the result of the proposed study.~* Subject is not covered by social security.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Quantra System with the QStat Cartridge (Type: EXPERIMENTAL): Decisions regarding transfusion of blood products will be made based on information derived from the Quantra System with the QStat Cartridge.
- Standard Laboratory Coagulation Testing (Type: ACTIVE_COMPARATOR): Decisions regarding transfusion of blood products will be made based on the site's standard of care which is information derived from standard laboratory coagulation tests.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Decrease of Lesions Induced by Mechanical Ventilation During ARDS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* severe ARDS with a PaO2 / FiO2 ratio ≤ 70 mmHg (for at least 2h) measured at PEEP\> 10 cmH2O and FiO2 = 1~* OR a severe ARDS with a PaO2 / FiO2\> 70 ratio but \<100 mmHg with a plateau pressure\> 35 cmH2O and a pH \<7.20~Exclusion Criteria:~* Patients with associated hemodynamic failure requiring veno-arterial ECMO~* Impossibility of setting up or contraindication to the placement of an esophageal tube~* Impossibility of realization of ventral decubitus~* Patient to receive corticosteroids during the first 48 hours following venous venous ECMO.~* Patients assisted by veno-venous ECMO for more than 24 hours.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- ultra-protective multimodal ventilation group (Type: EXPERIMENTAL): Patient will be diposed on ventral decubitus: one session at least more than 12 hours between inclusion and H48
- protective ventilation group (Type: NO_INTERVENTION): Patient will received usual care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility